Access cutting-edge chronic spontaneous urticaria treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access chronic spontaneous urticaria specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic spontaneous urticaria treatment provided free
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when administered as an add-on treatment to second generation H1-antihistamines (sgH1-AH) (standard label dose as background therapy) in adult US participants with moderat
Sponsor: Novartis Pharmaceuticals
Check if you qualify for this chronic spontaneous urticaria clinical trial in Birmingham, AL
If you're searching for chronic spontaneous urticaria treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic spontaneous urticaria specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.